Literature DB >> 1412382

Added hospital stay due to wound infections following cardiac surgery.

I Kappstein1, G Schulgen, G Fraedrich, V Schlosser, M Schumacher, F D Daschner.   

Abstract

To determine the prolongation of hospital stay due to postoperative wound infections following cardiac surgery, a prospective cohort study was performed by matching multiple control patients without infection to each infected patient (= case). Out of 22 cases, no patient died. No case had to be excluded from the matching process because of a lack of suitable control patients. The maximum number of controls per case was 10. The mean added stay was 12.2 days constituting a considerable prolongation of stay due to wound infection in cardiac surgery.

Entities:  

Mesh:

Year:  1992        PMID: 1412382     DOI: 10.1055/s-2007-1020134

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  13 in total

1.  Surgical site infection - a European perspective of incidence and economic burden.

Authors:  David J Leaper; Harry van Goor; Jacqueline Reilly; Nicola Petrosillo; Heinrich K Geiss; Antonio J Torres; Anne Berger
Journal:  Int Wound J       Date:  2004-12       Impact factor: 3.315

2.  Estimation of prolongation of hospital stay attributable to nosocomial infections: new approaches based on multistate models.

Authors:  G Schulgen; M Schumacher
Journal:  Lifetime Data Anal       Date:  1996       Impact factor: 1.588

3.  Daptomycin as a possible new treatment option for surgical management of Methicillin-Resistant Staphylococcus aureus sternal wound infection after cardiac surgery.

Authors:  Aron F Popov; Jan D Schmitto; Theodor Tirilomis; Christian Bireta; Kasim O Coskun; Suyog A Mokashi; Alexander Emmert; Martin Friedrich; Christoph H Wiese; Friedrich A Schoendube
Journal:  J Cardiothorac Surg       Date:  2010-08-06       Impact factor: 1.637

4.  [IKOP-Infection control in the operating theatreConsensus on the theme "Barrier measures during operations and invasive procedures"].

Authors:  B Salzberger; M Dettenkofer; F M Baer; O Cornely; M Herrmann; J Höher; S Lemmen
Journal:  Anaesthesist       Date:  2004-08       Impact factor: 1.041

5.  Adjunctive Hyperbaric Oxygen Therapy or Alone Antibiotherapy? Methicillin Resistant Staphylococcus aureus Mediastinitis in a Rat Model.

Authors:  Tolga Kurt; Ahmet Vural; Ahmet Temiz; Ersan Ozbudak; Ali Umit Yener; Suzan Sacar; Mustafa Sacar
Journal:  Braz J Cardiovasc Surg       Date:  2015 Sep-Oct

6.  Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model.

Authors:  Y Barnea; S Navon-Venezia; B Kuzmenko; N Artzi; Y Carmeli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-14       Impact factor: 3.267

7.  Treatment of gram-positive deep sternal wound infections in cardiac surgery--experiences with daptomycin.

Authors:  Aron F Popov; Jan D Schmitto; Ahmad F Jebran; Christian Bireta; Martin Friedrich; Direndra Rajaruthnam; Kasim O Coskun; Anselm Braeuer; Jose Hinz; Theodor Tirilomis; Friedrich A Schoendube
Journal:  J Cardiothorac Surg       Date:  2011-09-19       Impact factor: 1.637

8.  Hyperbaric oxygen therapy as an adjunctive treatment for sternal infection and osteomyelitis after sternotomy and cardiothoracic surgery.

Authors:  Wen-Kuang Yu; Yen-Wen Chen; Huei-Guan Shie; Te-Cheng Lien; Hsin-Kuo Kao; Jia-Horng Wang
Journal:  J Cardiothorac Surg       Date:  2011-10-17       Impact factor: 1.637

9.  Standard abdominal wound edge protection with surgical dressings vs coverage with a sterile circular polyethylene drape for prevention of surgical site infections (BaFO): study protocol for a randomized controlled trial.

Authors:  André L Mihaljevic; Christoph W Michalski; Mert Erkan; Carolin Reiser-Erkan; Carsten Jäger; Tibor Schuster; Christoph Schuhmacher; Jörg Kleeff; Helmut Friess
Journal:  Trials       Date:  2012-05-15       Impact factor: 2.279

10.  Economics and preventing hospital-acquired infection.

Authors:  Nicholas Graves
Journal:  Emerg Infect Dis       Date:  2004-04       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.